Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04498481 · ClinicalTrials.gov registry record
Treatment AND Monitoring Patterns AND Clinical Outcomes IN Patients Receiving Palbociclib Combination Treatment (with AI OR Fulvestrant) FOR Hr+/her2- A/mbc IN A Community Oncology Setting.
A clinical trial of Breast Cancer, sponsored by Pfizer.
- Completed
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT04498481: Completed study of Breast Cancer, sponsored by Pfizer.
NCT04498481 is a study of Breast Cancer that has completed, run by Pfizer. The registered enrollment target is 1 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04498481, a study of Breast Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a retrospective, observational study that will document the treatment and monitoring patterns and clinical outcomes of patients diagnosed with HR+/HER2- a/mBC who received Palbociclib combination therapy with aromatase inhibitors or fulvestrant in the a/mBC community oncology setting.
Conditions Studied
Study Locations (1)
New York
- Pfizer United States - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2018-07-01 |
What the finished NCT04498481 record still lists
NCT04498481 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04498481 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04498481 about?
NCT04498481 is a clinical study titled "Treatment AND Monitoring Patterns AND Clinical Outcomes IN Patients Receiving Palbociclib Combination Treatment (with AI OR Fulvestrant) FOR Hr+/her2- A/mbc IN A Community Oncology Setting.". This is a retrospective, observational study that will document the treatment and monitoring patterns and clinical outcomes of patients diagnosed with HR+/HER2- a/mBC who received Palbociclib combination therapy with aromatase inhibitors or fulvestrant in the a/mBC community oncology setting.
What is the current status of trial NCT04498481?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2018-03-01. Estimated completion is 2018-07-01.
What conditions does trial NCT04498481 study?
This clinical trial studies the following conditions: Breast Cancer.
Who is sponsoring clinical trial NCT04498481?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04498481 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04498481's enrollment target sits among peer trials
1 1223rd of 1224 the lowest of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI